L’anticorps Humanized Monoclonal anti-CD80 (Galiximab Biosimilar) a été validé pour FACS et in vivo. Il convient pour détecter CD80 (Galiximab Biosimilar) dans des échantillons de Humain.
N° du produit ABIN7795110
Aperçu rapide pour Recombinant CD80 (Galiximab Biosimilar) anticorps (ABIN7795110)
Antigène
CD80 (Galiximab Biosimilar)
Type d'anticorp
Recombinant Antibody
Reactivité
Humain
Hôte
Humanized
Clonalité
Monoclonal
Conjugué
Cet anticorp CD80 (Galiximab Biosimilar) est non-conjugé
Application
Flow Cytometry (FACS), In vivo Studies (in vivo)
Classe de qualité
Research Grade
Expression System
Mammalian cells
Fonction
Galiximab Biosimilar, CD80 Monoclonal Antibody
Attributs du produit
A humanized IgG1 monoclonal antibody directed against CD80, the natural ligand for the T-cell antigen CD28 which mediates T-cell and B-cell adhesion. Galiximab binds to CD80 expressed on the cell surfaces of follicular lymphomas, resulting in antibody-dependent cell-mediated cytotoxicity (ADCC). CD80 is expressed on activated B-cells and gamma-interferon-stimulated monocytes and is often expressed at low levels on the surfaces of follicular lymphoma cells and other lymphoid malignancies. Galiximab, an IgG(1) anti-CD80 antibody, binds to CD80, a costimulatory molecule involved in T-cell activation. Reduction in lesional, activated T cells induces improvement in psoriatic plaques.